Abstracts Archive - Page 1314 of 2607 - ACR Meeting Abstracts

Abstract Number: 1915 • 2018 ACR/ARHP Annual Meeting
Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Soledad Retamozo^1,2,3, Alejandra Flores-Chavez^4,5,6, Belchin Kostov⁷, Antoni Sisó-Almirall⁸, Marta Pérez-de-Lis⁹, Roberto Pérez-Alvarez¹⁰, Pilar Brito-Zerón^11,12, Munther A Khamashta¹³ and Manuel Ramos-Casals¹⁴, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁵Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁶Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁷ABS Les Corts, CAPSE, Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁸Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, GESCLINIC, Barcelona, Barcelona, Spain, ⁹Department of Anesthesia, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain, ¹⁰Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹¹Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹³Lupus Research Unit, The Rayne Institute, Lupus Research Unit, The Rayne Institute, Kings' College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ¹⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona., Barcelona, Spain
Background/Purpose: The scenario of biological-triggered autoimmune diseases has dramatically changed in recent years due to the increasing use of biologics in patients with solid cancers. Methods:…
Abstract Number: 1916 • 2018 ACR/ARHP Annual Meeting
Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Christopher McMaster^1,2, David Liew^3,4, Pallavi Shamdasani⁵, Jessica Leung^3,4, Albert Frauman^6,7, Jonathan Cebon^7,8 and Russell Buchanan^4,9, ¹Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Australia, ²Health and Biomedical Informatics Centre, University of Melbourne, Parkville, Australia, ³Medicine, University of Melbourne, Parkville VIC, Australia, ⁴Rheumatology, Austin Health, Heidelberg VIC, Australia, ⁵Department of Rheumatology, Austin Health, Heidelberg, Australia, ⁶Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ⁷Medicine, University of Melbourne, Melbourne, Australia, ⁸Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia, ⁹Medicine, University of Melbourne, Parkville, Australia
Background/Purpose: Rheumatic immune-related adverse events (irAEs) from PD-1 inhibitor immune checkpoint immunotherapy can not only lead to cessation of immunotherapy, but also can be disabling…
Abstract Number: 1917 • 2018 ACR/ARHP Annual Meeting
Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
Yvonne C. Lee¹, Bing Lu², Hongshu Guan³, Jeffrey Greenberg⁴, Joel Kremer⁵ and Daniel Solomon⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Experts have implicated physician prescribing rates as a contributing factor to the opioid crisis. However, little is known about heterogeneity in these patterns and…
Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Yvonne C. Lee¹, Patricia Katz^2,3, Amanda Quebe⁴, Luna Sun⁴, Himanshu Patel⁴, Carol L. Gaich⁴, Natalie Boytsov⁴ and Kaleb Michaud^5,6, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ³University of California San Francisco, San Francisco, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…
Abstract Number: 1919 • 2018 ACR/ARHP Annual Meeting
Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
Cecilia P. Chung¹, S. Todd Callahan², William Cooper², William Dupont³, Katherine Murray¹, Andrew Franklin⁴, Kathi Hall⁵, Judith A. Dudley⁵, C. Michael Stein¹ and Wayne Ray⁵, ¹Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ⁴Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, ⁵Health Policy, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hydrocodone, codeine, oxycodone, and tramadol are frequently prescribed for moderate pain in adolescents. However, pharmacokinetic and pharmacodynamic differences between these short-acting opioids could affect…
Abstract Number: 1920 • 2018 ACR/ARHP Annual Meeting
Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
Priyanka Ballal¹, Joachim Scholz², Laura Frey-Law³, Na Wang¹, Michael C. Nevitt⁴, Cora E. Lewis⁵ and Tuhina Neogi⁶, ¹Boston University School of Medicine, Boston, MA, ²Departments of Anesthesiology and Pharmacology, Columbia University Medical Center, New York, NY, ³University of Iowa, Iowa City, IA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Self-reported descriptors of pain in knee osteoarthritis (OA) such as burning and stabbing pain are suggestive of a neuropathic component of pain beyond that…
Abstract Number: 1921 • 2018 ACR/ARHP Annual Meeting
Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain
Tuhina Neogi¹, Na Wang², Cora E. Lewis³, Michael C. Nevitt⁴ and Laura Frey-Law⁵, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³University of Alabama Birmingham, Birmingham, AL, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Iowa, Iowa City, IA
Background/Purpose: Alterations in pain processing, such as pain sensitization and inadequate conditioned pain modulation (CPM), may contribute to the observed pain persistence post-knee replacement (KR)…
Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
James Campbell, Randall Stevens and Peter Hanson, Centrexion Therapeutics, Boston, MA
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…
Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Elena Nikiphorou¹, Sam Norton², Adam Young³, Lewis Carpenter², Josh Dixey⁴, David Walsh⁵ and Patrick Kiely⁶, ¹Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, ²Academic Rheumatology, King's College London, London, United Kingdom, ³University of Hertfordshire, Hertford, United Kingdom, ⁴Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁶Rheumatology Dept, St Georges Hospital, London, Great Britain
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
Abstract Number: 1924 • 2018 ACR/ARHP Annual Meeting
Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
Maria I. Danila¹, Lang Chen¹, Justin K Owensby¹, Ronan O'Beirne¹, Joshua A. Melnick¹, Eric M. Ruderman², Leslie R. Harrold³ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Controlling disease activity in RA using a treat-to-target (T2T) strategy can optimize clinical and patient-important outcomes. Yet, many patients are not familiar with T2T…
Abstract Number: 1925 • 2018 ACR/ARHP Annual Meeting
Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?
Jennifer Barton^1,2, Shelia Markwardt², Allison Schue¹, Somnath Saha^2,3 and Edward H. Yelin⁴, ¹VA Portland Health Care System, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Medicine, VA Portland Health Care System, Portland, OR, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Goal concordance between patients with chronic diseases and their clinicians has been linked to improved outcomes, but not explored in rheumatoid arthritis (RA). Our…
Abstract Number: 1926 • 2018 ACR/ARHP Annual Meeting
Effects of Social Networking on Chronic Disease Management in Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Jessica Foreman², Heather Lin³, Cheuk Hong Leung⁴, Tiffany Westrich-Robertson⁵, Catherine Hofstetter⁶, Susan K. Peterson⁷, Anne Lyddiatt⁸, Amye L. Leong⁹, Irmgard U. Willcockson¹⁰ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵International Foundation for Autoimmune and Autoinflammatory Arthritis, Saint Louis, Missouri, USA, St Louis, MO, ⁶OMERACT patient research partner group, Ottawa, ON, Canada, ⁷Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston Texas, USA, Houston, TX, ⁸Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ⁹Spokesperson; Strategic Relations, Bone and Joint Decade, Santa Barbara, CA, ¹⁰School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: We evaluated a social networking intervention to help patients with rheumatoid arthritis become active partners in their own care. We developed a closed independent…
Abstract Number: 1927 • 2018 ACR/ARHP Annual Meeting
Do Remission and Low Disease Activity State Go Hand in Hand with Patient’s Perception of Disease Burden and Quality of Life in Systemic Lupus Erythematosus?
Chiara Tani¹, Elena Elefante¹, Chiara Stagnaro², Viola Signorini², Linda Carli¹, Meenakshi Jolly³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Pisa, Rheumatology Unit, PISA, Italy, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Disease remission is the ideal treatment target in SLE; when remission cannot be reached, the lowest possible disease activity state should be targeted. Available…
Abstract Number: 1928 • 2018 ACR/ARHP Annual Meeting
Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis
K. Julia Kaal¹, Nick Bansback^1,2,3, Aslam Anis^4,5 and Mark Harrison^5,6,7,8, ¹University of British Columbia, Vancouver, BC, Canada, ²St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, School of Population and Public Health, Vancouver, BC, Canada, ⁵Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁸Collaborations in Outcomes Research and Evaluation, Vancouver, BC, Canada
Background/Purpose: Patients often have to pay for prescription medications out-of-pocket and cost-related nonadherence is a recognized problem. The treatment of rheumatoid arthritis is associated with…
Abstract Number: 1929 • 2018 ACR/ARHP Annual Meeting
The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
Daniel Boulos¹, Robert Metcalf², Susanna Proudman³ and Ian Wicks⁴, ¹Rheumatology, Royal Melbourne Hospital, Melbourne, Melbourne, Australia, ²Rheumatology, Royal Adelaide Hospital, Adelaide, Adelaide, Australia, ³Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁴Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia
Background/Purpose: To assess whether the neutrophil-lymphocyte ratio (NLR) can predict those who require disease modifying therapy escalation and hence progression in rheumatoid arthritis (RA). Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].